Parkinson's Disease Hijacks the Body's Energy Engine, Study Finds

Weight loss in Parkinson's disease has puzzled clinicians for decades. Patients shed kilograms as the disease advances, yet the cause has never been clearly pinned down. Is it muscle wasting? Swallowing difficulties that limit food intake? Something more fundamental happening inside cells? A study published November 30, 2025, in the Journal of Neurology, Neurosurgery and Psychiatry provides the clearest answer yet - and it implicates a failure deep within the body's energy-production machinery.

Led by Professor Hirohisa Watanabe and colleagues at Fujita Health University in Japan, the research enrolled 91 patients with Parkinson's disease and 47 healthy controls. Using two complementary methods - bioelectrical impedance analysis to measure body composition and mass spectrometry-based metabolomics to profile circulating biochemicals - the team built a detailed picture of both what patients were losing and why.

Fat Goes. Muscle Stays.

The body composition data delivered a clear surprise. Parkinson's patients had significantly lower body weight and body mass index compared with healthy controls, but that weight difference came almost entirely from reduced fat mass. Muscle mass was largely preserved, particularly in early and mid-stage disease. The prevalence of sarcopenia - the medical term for muscle loss - was comparable to what would be expected in the general aging population.

"We clarified that it is not the muscle that is decreasing, but the fat," said Professor Watanabe. "This changes how we should think about weight loss in Parkinson's disease."

That distinction matters clinically. Muscle wasting has different causes and consequences than fat depletion. If clinicians assume that Parkinson's weight loss means lost muscle, nutritional interventions will be calibrated incorrectly. The new data suggest the problem is not that patients are failing to consume enough protein to maintain muscle - it is that their cells are consuming fat as a fuel source even when other nutrients are available.

When the Main Engine Fails

The metabolomics data explained the fat loss. Two key metabolites of the standard glucose-burning pathway were significantly reduced in Parkinson's patients: lactic acid, a product of glycolysis, and succinic acid, a product of the Krebs cycle (also called the TCA cycle). Both pathways together form the body's primary mechanism for converting glucose into adenosine triphosphate - the universal cellular energy currency. Their suppression signals that the main metabolic engine is running poorly.

When cells cannot efficiently extract energy from glucose, the body activates a backup system. Ketone bodies - small molecules produced from fat - can substitute for glucose as a fuel source, particularly for the brain and heart. The Fujita team found elevated levels of acetoacetic acid, a major ketone body, in Parkinson's patients. Markers of amino acid catabolism, which also reflects the body breaking down its own tissues for fuel, were elevated as well.

"Being thin may signal an invisible energy crisis occurring inside the patient's body," said Dr. Atsuhiro Higashi, co-author of the study. "The body is forced to burn fat to survive."

This metabolic shift was not uniform. Ketone body levels were highest in the thinnest patients and in those with more advanced disease severity, suggesting a progressive pattern: as Parkinson's advances and carbohydrate metabolism deteriorates further, reliance on fat-burning intensifies. The thinnest, most advanced patients are burning the most fat - and have the least of it left to burn.

Implications for How Parkinson's Is Treated

Standard Parkinson's treatment centers on dopamine replacement, particularly with levodopa. Nutritional guidance has historically emphasized adequate calorie intake to prevent unintentional weight loss. The new findings challenge whether that guidance is sufficient.

If the body's glucose-burning pathways are impaired at a mitochondrial level, simply adding more calories does not address the underlying problem. The cells may still be unable to efficiently extract energy from carbohydrates regardless of how much is consumed. This suggests a potential role for interventions that target mitochondrial function directly - compounds that improve the efficiency of the Krebs cycle, or therapeutic strategies that deliberately support ketone availability to help cells meet their energy needs.

The study was not designed to test treatments, and no intervention conclusions can be drawn from its observational findings. What it does establish is a mechanistic framework: Parkinson's disease involves not just dopamine loss but a broader energy-metabolism failure that selectively depletes body fat and forces the body into a metabolic state more commonly associated with fasting or starvation.

Study Limits and What Comes Next

The 91-patient sample, drawn from a single Japanese tertiary care center, is relatively small for metabolomic research of this kind. The patient group was older and had moderate disease severity on average; findings may not fully represent early-stage patients or those with atypical Parkinson's variants. The cross-sectional design also means the data capture a single time point per patient - it cannot prove that metabolic failure causes fat loss rather than the reverse, or that both are driven by a common underlying factor.

Longitudinal studies tracking the same patients over years, alongside controlled dietary intervention trials, will be needed to establish causality and identify whether metabolic support translates into better outcomes. Still, by establishing that fat loss - not muscle loss - is the primary body-composition signature of Parkinson's weight decline, and by linking it directly to measurable failures in glycolysis and the Krebs cycle, the study redirects both research and clinical attention toward a part of the disease that has been underexplored.